Retinal Artery Occlusions: To tPA or Not to tPA?

With increasing awareness that a retinal artery occlusion (RAO) is a type of stroke, ophthalmologists must be able to plan the next steps of care when an RAO is identified on exam. Drs. Amanda Henderson and Michael Carper join host Amanda Redfern guide us through their recommendations and various tricky scenarios, notably whether or not to advise use of tissue plasminogen activator (tPA)

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

CME Information

Release: May 16, 2024; expires May 16, 2027

Financial Disclosures:
Planner/Faculty: Dr. Redfern reports no relevant financial disclosures.
Faculty: Drs. Henderson and Carper report no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.

Learning Objective: Upon completion of this episode, the listener should be able to describe how to manage patients diagnosed with retinal artery occlusion, especially cases in which to consider the use of thrombolytic therapy.

Audience: This activity is intended for comprehensive ophthalmologists.

Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.